Table 1.
Preoperative baseline characteristics of enrolled patients according to active surveillance protocol stratified by race/ethnicity
| UCSF Criteria |
NCCN Criteria |
|||||
|---|---|---|---|---|---|---|
| Variables | WA Men (N = 196) |
AA Men (N = 191) |
P Value | WA Men (N = 124) |
AA Men (N = 148) |
P Value |
| Median age (range) | 56.0 (36–74) | 59.0 (36–77) | <.001 | 60.0 (55–74) | 60.0 (55–77) | .494 |
| BMI (kg/m2) | 26.9 ± 3.2 | 26.4 ± 3.8 | .222 | 26.3 ± 3.0 | 26.2 ± 3.9 | .832 |
| PSA (ng/mL) | 4.97 ± 1.90 | 4.80 ± 2.05 | .405 | 5.23 ± 2.00 | 5.08 ± 1.94 | .524 |
| Biopsy Gleason score | 6 | 6 | 1 | 6 | 6 | 1 |
| Clinical stage (%) | .496 | .473 | ||||
| T1c | 179 (91.3) | 170 (89.0) | 110 (88.7) | 126 (85.1) | ||
| T2a | 17 (8.7) | 21 (11.0) | 14 (11.3) | 22 (14.9) | ||
| Positive cores (%) | .065 | .046 | ||||
| Single | 101 (51.5) | 117 (61.3) | 68 (54.8) | 99 (66.9) | ||
| Multiple | 95 (48.5) | 74 (38.7) | 56 (45.2) | 49 (33.1) | ||
| Percentage of maximum core | 15.3 ± 8.7 | 11.5 ± 8.4 | <.001 | 20.4 ± 14.6 | 15.0 ± 13.2 | .001 |
AA, African-American; BMI, body mass index; NCCN, National Comprehensive Cancer Network; PSA, prostate-specific antigen; UCSF, University of California San Francisco; WA, White-American.